Study	Reason for exclusion
Bancalari 2016	Data from VLBW infants (n = 47) with stage 2 or 3 ROP in zone II‐III were retrospectively analysed. Authors assessed the effect of propranolol on progression of ROP. Infants in the intervention group received propranolol. Outcomes of the intervention group were compared to a historical control group not receiving propranolol. Excluded because the study was not a randomised or quasi‐randomised trial.
Filippi 2016	Preterm neonates (n = 23, gestational age < 32 weeks) with stage 2 ROP, zone II without plus disease received propranolol as ophthalmic solution until complete development of retinal vascularisation, but no more than 60 days. Trial was discontinued early. Excluded because the study was not a randomised or quasi‐randomised trial.
Makhoul 2013	Preterm infants (n = 20, gestational age 23 to 28 weeks) with stage 1 (zone I) ROP, stage 2 or higher (zone I or II) ROP, and/or plus disease were randomised to receive propranolol or placebo. Outcomes included progression of ROP and need for invasive interventions. This study was published as a research letter. Excluded because methodological details could not be fully clarified and due to 85% loss to follow‐up (17/20 patients lost to follow‐up).